Skip to main navigation Skip to search Skip to main content

Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

  • Stefanie Schmidt
  • , Frank Kunath
  • , Bernadette Coles
  • , Desiree Louise Draeger
  • , Laura Maria Krabbe
  • , Rick Dersch
  • , Katrin Jensen
  • , Philipp Dahm
  • , Joerg J. Meerpohl

Research output: Contribution to journal › Article › peer-review

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of bacillus Calmette-Guérin (BCG) intravesical therapy compared to mitomycin C (MMC) intravesical therapy for treating Ta and T1 bladder cancer in adults.

Original languageEnglish (US)
Article numberCD011935
JournalCochrane Database of Systematic Reviews
Volume2015
Issue number11
DOIs
StatePublished - Nov 5 2015

Bibliographical note

Publisher Copyright:
© 2015 The Cochrane Collaboration.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer'. Together they form a unique fingerprint.

Cite this